

Appendix 6. Baseline characteristics of survey respondents compared to entire sample and dataset

		Dataset from which sample was drawn [#]	Entire sample, including non- respondents	All respondents, including anonymous	Respondents, excluding anonymous
		(N=2755) n (%)	(N=404) n (%)	(N=149) n (%)	(N=73) n (%)
Registrant country	Australia	1649 (59.9)	264 (65.3)	46 (30.9)	46 (63.0)
	New Zealand	238 (8.6)	36 (8.9)	10 (6.7)	10 (13.7)
	Egypt	93 (3.4)	15 (3.7)	3 (2.0)	3 (4.1)
	Malaysia	29 (1.1)	4 (1.0)	2 (1.3)	2 (2.7)
	Turkey	78 (2.8)	14 (3.5)	2 (1.3)	2 (2.7)
	Brazil	97 (3.5)	16 (4.0)	2 (1.3)	2 (2.7)
	Poland	20 (0.7)	2 (0.5)	2 (1.3)	2 (2.7)
	Italy	39 (1.4)	5 (1.2)	2 (1.3)	2 (2.7)
	Greece	23 (0.8)	2 (0.5)	1 (0.7)	1 (1.4)
	Switzerland	40 (1.5)	4 (1.0)	1 (0.7)	1 (1.4)
	USA	38 (1.4)	8 (2.0)	1 (0.7)	1 (1.4)
	China	48 (1.7)	7 (1.7)	1 (0.7)	1 (1.4)
	Anonymous/missing*	-	-	76 (51.0)	-
Primary sponsor type	University	912 (33.1)	135 (33.4)	26 (17.4)	26 (35.6)
	Individual	754 (27.4)	111 (27.5)	21 (14.1)	21 (28.8)
	Hospital	495 (18.0)	75 (18.6)	13 (8.7)	13 (17.8)
	Government body	140 (5.1)	18 (4.5)	7 (4.7)	7 (9.6)
	Other collaborative groups	66 (2.4)	10 (2.5)	4 (2.7)	4 (5.5)
	Commercial sector/Industry	240 (8.7)	36 (8.9)	2 (1.3)	2 (2.7)
	Charities/societies/foundations	91 (3.3)	12 (3.0)	0 (0.0)	0 (0.0)
	Other	57 (2.1)	7 (1.7)	0 (0.0)	0 (0.0)
	Anonymous/missing*	-	-	76 (51.0)	-
Primary sponsor type – grouped	Industry	240 (8.7)	36 (8.9)	2 (1.3)	2 (2.7)
	Non-industry	2515 (91.3)	368 (91.1)	71 (47.7)	71 (97.3)
	Anonymous/missing*	-	-	76 (51.0)	-
Intervention type	Drug	746 (18.9)	102 (25.2)	12 (8.1)	12 (16.4)
	Non-drug	3201 (81.1)	302 (74.8)	61 (40.9)	61 (83.6)
	Anonymous/missing*	-	-	76 (51.0)	-
Sample size [^]	<100	1746 (63.4)	267 (66.1)	37 (24.8)	37 (50.7)
	100-500	805 (29.2)	107 (26.5)	29 (19.5)	29 (39.7)
	>500	204 (7.4)	30 (7.4)	7 (4.7)	7 (9.6)
	Anonymous/missing*	-	-	76 (51.0)	-
Registration year	2010	499 (18.1)	77 (19.1)	9 (6.0)	9 (12.3)
	2011	514 (18.7)	76 (18.8)	11 (7.4)	11 (15.1)
	2012	423 (15.4)	59 (14.6)	13 (8.7)	13 (17.8)
	2013	428 (15.6)	65 (16.1)	10 (6.7)	10 (13.7)
	2014	405 (14.7)	55 (13.6)	15 (10.1)	15 (20.5)
	2015	486 (17.6)	72 (17.8)	15 (10.1)	15 (20.5)
	Anonymous/missing*	-	-	76 (51.0)	-
Recruitment start year ⁺	<2010	705 (25.6)	96 (23.8)	15 (10.1)	15 (20.5)
	2010	461 (16.7)	80 (19.8)	10 (6.7)	10 (13.7)
	2011	370 (13.4)	58 (14.4)	16 (10.7)	16 (21.9)
	2012	343 (12.5)	55 (13.6)	12 (8.1)	12 (16.4)
	2013	319 (11.6)	40 (9.9)	5 (3.4)	5 (6.8)
	2014	287 (10.4)	36 (8.9)	8 (5.4)	8 (11.0)
	2015	270 (9.8)	39 (9.7)	7 (4.7)	7 (9.6)
	Anonymous/missing*	-	-	76 (51.0)	-
Allocation	Randomised	2045 (74.2)	304 (75.2)	51 (34.2)	51 (69.9)
	Non-randomised	710 (25.8)	100 (24.8)	22 (14.8)	22 (30.1)
	Anonymous/missing*	-	-	76 (51.0)	-
Days between enrolment start and retrospective registration - Median (IQR)		242 (713)	224.5 (802)	387 (877) (n=76 missing)	387 (877)

[#] All retrospectively registered interventional trials on ANZCTR between 1 Jan 2010 – 31 Dec 2015

* Survey respondents could choose to remain anonymous, therefore data not available

[^] Actual sample size where available, otherwise target sample size used.

⁺ Actual date of first participant enrolment where available, otherwise anticipated date of first participant enrolment used.